NCT00631462 - A Dose-escalation Study of the Safety and Tolerability of Orally Administered TG101348 in Patients With Myelofibrosis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2008

Primary Completion Date

October 31, 2009

Study Completion Date

October 31, 2009

Conditions

Myelofibrosis

Interventions

DRUG

TG101348

Orally administered, once a day, for 28 days, up to 6 cycles.

Trial Locations (6)

University of Michigan Comprehensive Cancer Center, Ann Arbor

Mayo Clinic, Rochester, Rochester

MD Anderson Cancer Center, Houston

UCSD Moores Cancer Center, San Diego

Stanford Comprehensive Cancer Center, Stanford

Dana Farber Cancer Institute, Boston